Shanghai InnoStar Bio-tech Co Share Buybacks
Share Buybacks of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 16, 2026.
Get this data via API
Financial Data API
Share Buybacks
-CNY
Last updated:
Share Buybacks of Shanghai InnoStar Bio-tech Co is 2026 - CNY. Share Buybacks of Shanghai InnoStar Bio-tech Co was 2025 627.00 M CNY. It decreases by % lower compared to the previous year.
The Shanghai InnoStar Bio-tech Co Share Buybacks history
3 Years
10 Years
25 Years
Max
Share Buybacks
Date
Share Buybacks
Jan 1, 2022
570.00 M CNY
Jan 1, 2023
0.00 CNY
Jan 1, 2024
627.00 M CNY
| YEAR | Share Buybacks | YoY |
|---|---|---|
| 627.00 MCNY | — | |
| 0.00CNY | -100.00% | |
| 570.00 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Shanghai InnoStar Bio-tech Co Stock analysis
What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd is a company based in Shanghai, China, operating within the Life Sciences Tools & Services sector of the Health Care industry. The company has 1,085 employees and completed its initial public offering (IPO) on September 3, 2024. It provides biopharmaceutical non-clinical research services, focusing on early drug development evaluation, non-clinical research, and clinical testing and translational research. The early drug development evaluation involves creating multiple early toxicity rapid prediction and screening models. Non-clinical research encompasses safety evaluation, pharmacokinetic research, and pharmacodynamic research. Clinical testing and translational research offers analytical methods and data support for clinical pharmacokinetics, efficacy, and safety studies related to innovative drug projects. The company's headquarters are located in Shanghai, and it maintains a website at www.innostar.cn. Its stock is listed under the ticker 688710.SS with ISIN CNE1000078J7. Shanghai InnoStar Bio-tech Co Ltd serves the biopharmaceutical sector by supporting the development and evaluation of new drugs through specialized research services. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock
On Eulerpool you can find the complete historical development of Share Buybacks Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.
Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.
Share Buybacks's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Shanghai InnoStar Bio-tech Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Shanghai InnoStar Bio-tech Co
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Shanghai InnoStar Bio-tech Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth